- Home
- RGNX vs ZVRA Comparison
RGNX vs ZVRA Comparison
Compare RGNX & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- ZVRA
- Stock Information
- Founded
- RGNX 2008
- ZVRA 2006
- Country
- RGNX United States
- ZVRA United States
- Employees
- RGNX N/A
- ZVRA N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- ZVRA Health Care
- Exchange
- RGNX Nasdaq
- ZVRA Nasdaq
- Market Cap
- RGNX 451.1M
- ZVRA 467.6M
- IPO Year
- RGNX 2015
- ZVRA 2015
- Fundamental
- Price
- RGNX $12.50
- ZVRA $11.02
- Analyst Decision
- RGNX Strong Buy
- ZVRA Strong Buy
- Analyst Count
- RGNX 8
- ZVRA 8
- Target Price
- RGNX $28.50
- ZVRA $22.57
- AVG Volume (30 Days)
- RGNX 525.7K
- ZVRA 2.6M
- Earning Date
- RGNX 11-05-2025
- ZVRA 11-11-2025
- Dividend Yield
- RGNX N/A
- ZVRA N/A
- EPS Growth
- RGNX N/A
- ZVRA N/A
- EPS
- RGNX N/A
- ZVRA N/A
- Revenue
- RGNX $155,782,000.00
- ZVRA $62,020,000.00
- Revenue This Year
- RGNX $203.79
- ZVRA $336.43
- Revenue Next Year
- RGNX $0.72
- ZVRA $54.26
- P/E Ratio
- RGNX N/A
- ZVRA N/A
- Revenue Growth
- RGNX 74.95
- ZVRA 161.81
- 52 Week Low
- RGNX $5.04
- ZVRA $6.19
- 52 Week High
- RGNX $12.28
- ZVRA $13.16
- Technical
- Relative Strength Index (RSI)
- RGNX 76.74
- ZVRA 65.95
- Support Level
- RGNX $10.24
- ZVRA $9.08
- Resistance Level
- RGNX $11.00
- ZVRA $11.08
- Average True Range (ATR)
- RGNX 0.63
- ZVRA 0.66
- MACD
- RGNX 0.28
- ZVRA 0.28
- Stochastic Oscillator
- RGNX 93.57
- ZVRA 93.32
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.